Seaport Therapeutics Says Drug Potentially Reduces Liver Impact of Depression Treatment

MT newswire2026/10/09 12:01

08:01 AM EDT, 10/09/2026 (MT Newswires) -- Seaport Therapeutics' (SPTX) GlyphAgo showed a "statistically significant" 6.8-fold increase in bioavailability of the antidepressant agomelatine compared with unmodified agomelatine in a 174-patient phase 1 clinical trial, the company said Friday. GlyphAgo, designed to enhance lymphatic absorption of agomelatine, also achieved "therapeutically relevant" exposure of agomelatine at substantially lower doses meant to reduce liver damage, the company said. The drug also potentially reduces the risk of liver damage and the need for routine liver monitoring that has curtailed agomelatine's use to treat severe depression.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

UK funds significantly reduced their holdings in SpaceX last week and had fully exited Tesla as of April.

格隆汇•2026/11/09 05:55

Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF

FXStreet•2026/11/09 05:45

Sun Machinery CEO Park Kyung-hee Raises Stake to 8.40% From 8.31%

Bitget•2026/11/09 05:37

The central bank has increased its gold reserves for 24 consecutive months, with October’s increase hitting a record high for the period.

新浪财经•2026/11/09 05:37